12 results on '"Salwender, Hans"'
Search Results
2. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
- Author
-
Weinhold, Niels, primary, Salwender, Hans J., additional, Cairns, David A., additional, Raab, Marc S., additional, Waldron, George, additional, Blau, Igor W., additional, Bertsch, Uta, additional, Hielscher, Thomas, additional, Morgan, Gareth J., additional, Jauch, Anna, additional, Davies, Faith E., additional, Hänel, Mathias, additional, Cook, Gordon, additional, Scheid, Christoph, additional, Houlston, Richard, additional, Goldschmidt, Hartmut, additional, Jackson, Graham, additional, and Kaiser, Martin F., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
- Author
-
Merz, Maximilian, primary, Jauch, Anna, additional, Hielscher, Thomas, additional, Mai, Elias K., additional, Seckinger, Anja, additional, Hose, Dirk, additional, Bertsch, Uta, additional, Neben, Kai, additional, Raab, Marc S., additional, Salwender, Hans, additional, Blau, Igor W., additional, Lindemann, Hans-Walter, additional, Schmidt-Wolf, Ingo, additional, Scheid, Christof, additional, Haenel, Mathias, additional, Weisel, Katja, additional, Goldschmidt, Hartmut, additional, and Hillengass, Jens, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
- Author
-
Straka, Christian, primary, Liebisch, Peter, additional, Salwender, Hans, additional, Hennemann, Burkhard, additional, Metzner, Bernd, additional, Knop, Stefan, additional, Adler-Reichel, Sigrid, additional, Gerecke, Christian, additional, Wandt, Hannes, additional, Bentz, Martin, additional, Bruemmendorf, Tim Hendrik, additional, Hentrich, Marcus, additional, Pfreundschuh, Michael, additional, Wolf, Hans-Heinrich, additional, Sezer, Orhan, additional, Bargou, Ralf, additional, Jung, Wolfram, additional, Trümper, Lorenz, additional, Hertenstein, Bernd, additional, Heidemann, Else, additional, Bernhard, Helga, additional, Lang, Nicola, additional, Frickhofen, Norbert, additional, Hebart, Holger, additional, Schmidmaier, Ralf, additional, Sandermann, Andreas, additional, Dechow, Tobias, additional, Reichle, Albrecht, additional, Schnabel, Brigitte, additional, Schäfer-Eckart, Kerstin, additional, Langer, Christian, additional, Gramatzki, Martin, additional, Hinke, Axel, additional, Emmerich, Bertold, additional, and Einsele, Hermann, additional
- Published
- 2016
- Full Text
- View/download PDF
5. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study.
- Author
-
Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner EM, Schmid C, Reinhardt HC, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, and Wolschke C
- Subjects
- Humans, Middle Aged, Male, Female, Adult, Prospective Studies, Transplantation, Homologous, Treatment Outcome, Multiple Myeloma therapy, Multiple Myeloma mortality, Multiple Myeloma diagnosis, Thalidomide administration & dosage, Thalidomide therapeutic use, Hematopoietic Stem Cell Transplantation methods, Transplantation, Autologous, Maintenance Chemotherapy
- Abstract
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma is controversial. Between 2008 and 2014 a total of 217 multiple myeloma patients with a median age of 51 years were included by 20 German centers within an open-label, parallel-group, multicenter clinical trial to compare alloTSCT to autologous tandem transplantation (autoTSCT) followed by 2 years of maintenance therapy with thalidomide (100 mg/day) in both arms with respect to relapse/progression-free survival (PFS) and other relevant outcomes. A total of 178 patients underwent a second transplant (132 allogeneic, 46 autologous). PFS at 4 years after the second transplant was 47% (95% CI: 38-55%) for alloTSCT and 35% (95% CI: 21-49%) for autoTSCT (P=0.26). This difference increased to 22% at 8 years (P=0.10). The cumulative incidences of non-relapse mortality and of relapse at 4 years were 13% (95% CI: 8-20%) and 2% (95% CI: 0.3-2%) (P=0.044) and 40% (95% CI: 33-50%) and 63% (95% CI: 50-79%) (P=0.04) for alloTSCT and autoTSCT, respectively. The difference for relapse/progression increased to 33% (alloTSCT: 44%, autoTSCT: 77%) at a median follow-up of 82 months (P=0.002). Four-year overall survival was 66% (95% CI: 57-73%) for alloTSCT and 66% (95% CI: 50-78%) for autoTSCT (P=0.91) and 8-year overall survival was 52% and 50% (P=0.87), respectively. In conclusion, alloTSCT followed by thalidomide maintenance reduced the rate of recurrence or progression during a follow-up period of up to 10 years but failed to improve PFS significantly. This study was registered with ClinicalTrials.gov (NCT00777998).
- Published
- 2024
- Full Text
- View/download PDF
6. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
- Author
-
Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, and Goldschmidt H
- Subjects
- Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Bortezomib adverse effects, Humans, Induction Chemotherapy adverse effects, Induction Chemotherapy methods, Multiple Myeloma complications, Risk Factors, Bortezomib administration & dosage, Multiple Myeloma drug therapy, Peripheral Nervous System Diseases chemically induced
- Published
- 2016
- Full Text
- View/download PDF
7. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
- Author
-
Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, and Schlenk RF
- Subjects
- Adult, Aminoglycosides administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Comorbidity, Consolidation Chemotherapy, Cytarabine administration & dosage, Female, Gemtuzumab, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Mitoxantrone administration & dosage, Remission Induction, Salvage Therapy, Treatment Outcome, Tretinoin administration & dosage, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute therapy
- Abstract
Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51%) and partial remission in 10 (11%) patients resulting in an overall response rate of 61.5%; 33 (35.5%) patients had refractory disease and 3 patients (3%) died. Allogeneic hematopoietic cell transplantation was performed in 71 (76%) patients; 6 of the 71 (8.5%) patients developed moderate or severe sinusoidal obstruction syndrome after transplantation. Four-year overall survival rate was 32% (95% confidence interval 24%-43%). Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation (n=51) had a 4-year survival rate of 49% (95% confidence intervaI 37%-64%). Patients with fms-like tyrosine kinase internal tandem duplication positive acute myeloid leukemia had a poor outcome despite transplantation. In conclusion, the described regimen is an effective and tolerable salvage therapy for patients who are primary refractory to one cycle of conventional intensive induction therapy. (clinicaltrials.gov identifier: 00143975)., (Copyright© Ferrata Storti Foundation.)
- Published
- 2016
- Full Text
- View/download PDF
8. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
- Author
-
Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, and Jauch A
- Subjects
- Antineoplastic Agents therapeutic use, Gene Deletion, Gene Expression, Genetic Loci, Humans, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Mutagenesis, Insertional, Neoplasm Staging, Plasma Cells drug effects, Plasma Cells pathology, Ploidies, Prognosis, Proto-Oncogene Proteins c-myc metabolism, Survival Analysis, Chromosomes, Human, Pair 1 chemistry, Multiple Myeloma genetics, Plasma Cells metabolism, Proto-Oncogene Proteins c-myc genetics, Translocation, Genetic
- Published
- 2016
- Full Text
- View/download PDF
9. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
- Author
-
Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, and Goldschmidt H
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Bortezomib adverse effects, Cyclophosphamide administration & dosage, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Drug Administration Schedule, Female, Humans, Injections, Intravenous, Injections, Subcutaneous, Kidney drug effects, Kidney pathology, Male, Middle Aged, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Multiple Myeloma pathology, Neoplasm Staging, Peripheral Nervous System Diseases chemically induced, Peripheral Nervous System Diseases pathology, Prospective Studies, Remission Induction, Survival Analysis, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Bortezomib administration & dosage, Induction Chemotherapy methods, Multiple Myeloma drug therapy
- Abstract
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65%; subcutaneous=56%, P=0.02). Rates of grade 2 or more peripheral neuropathy were higher in patients treated with intravenous bortezomib during the third cycle (intravenous=8%; subcutaneous=2%, P=0.001). Overall response rates were similar in patients treated intravenously or subcutaneously. The presence of International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities did not have a negative impact on overall response rates in either group. To our knowledge this is the largest study to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The clinical trial is registered at eudract.ema.europa.eu as n. 2010-019173-16., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
10. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
- Author
-
Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, and Lokhorst HM
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Boronic Acids administration & dosage, Boronic Acids adverse effects, Bortezomib, Creatinine blood, Humans, Middle Aged, Multiple Myeloma mortality, Pyrazines administration & dosage, Pyrazines adverse effects, Remission Induction, Renal Insufficiency mortality, Renal Insufficiency physiopathology, Transplantation, Autologous, Treatment Outcome, Antineoplastic Agents therapeutic use, Boronic Acids therapeutic use, Hematopoietic Stem Cell Transplantation, Multiple Myeloma complications, Multiple Myeloma therapy, Pyrazines therapeutic use, Renal Insufficiency etiology, Renal Insufficiency prevention & control
- Abstract
Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma treated with bortezomib before and after autologous stem cell transplantation within a prospective randomized phase III trial. Eight hundred and twenty-seven newly diagnosed myeloma patients in the HOVON-65/GMMG-HD4 trial were randomized to receive three cycles of vincristine, adriamycin, dexamethasone (VAD) or bortezomib, adriamycin, dexamethasone (PAD) followed by autologous stem cell transplantation and maintenance with thalidomide 50 mg daily (VAD-arm) or bortezomib 1.3 mg/m(2) every 2 weeks (PAD-arm). Baseline serum creatinine was less than 2 mg/dL (Durie-Salmon-stage A) in 746 patients and 2 mg/dL or higher (stage B) in 81. In myeloma patients with a baseline creatinine ≥ 2 mg/dL the renal response rate was 63% in the VAD-arm and 81% in the PAD-arm (P=0.31). The overall myeloma response rate was 64% in the VAD-arm versus 89% in the PAD-arm with 13% complete responses in the VAD-arm versus 36% in the PAD-arm (P=0.01). Overall survival at 3 years for patients with a baseline creatinine ≥ 2 mg/dL was 34% in the VAD-arm versus 74% in the PAD-arm (P<0.001) with a progression-free survival rate at 3 years of 16% in the VAD-arm versus 48% in the PAD-arm (P=0.004). Overall and progression-free survival rates in the PAD-arm were similar in patients with a baseline creatinine ≥ 2 mg/dL or <2 mg/dL. We conclude that a bortezomib-containing treatment before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in patients with newly diagnosed multiple myeloma. The trial was registered at www.trialregister.nl as NTR213 and at www.controlled-trials.com as ISRCTN 64455289.
- Published
- 2014
- Full Text
- View/download PDF
11. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
- Author
-
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, and Goldschmidt H
- Subjects
- Adult, Aged, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine therapeutic use, Daunorubicin therapeutic use, Dexamethasone therapeutic use, Female, Humans, Male, Middle Aged, Remission Induction, Thioguanine therapeutic use, Treatment Outcome, Vincristine therapeutic use, Medical Oncology methods, Multiple Myeloma drug therapy, Thalidomide therapeutic use
- Abstract
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.
- Published
- 2008
- Full Text
- View/download PDF
12. The effects of rituximab treatment during pregnancy on a neonate.
- Author
-
Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, and Schmitz N
- Subjects
- Adult, Antibodies, Monoclonal blood, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Burkitt Lymphoma blood, Burkitt Lymphoma drug therapy, Child, Preschool, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Fetal Blood drug effects, Humans, Prednisone administration & dosage, Pregnancy, Rituximab, Vincristine administration & dosage, Antibodies, Monoclonal administration & dosage, Infant, Newborn blood, Prenatal Exposure Delayed Effects blood
- Abstract
A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy. Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations. B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.